| INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer and is the 6th most common malignancy in the United States (US).
1,2 Its annual US incidence is expected to double by 2030. 1, 3 In 2016, there were 39 000 new cases of HCC and 27 000 deaths. Even after potentially curative surgical extirpation, the 5-year survival rates are only 30% and 60% for resection and transplant, respectively. 4 Novel therapeutic strategies ought to be tested in clinical trials to further improve outcomes in this cohort of patients. A well-defined staging system which accurately discriminates prognosis is needed in order to accurately stratify patients for such studies.
Recently, the American Joint Committee on Cancer (AJCC) released the new 8th edition staging system (Table 1) , which
incorporates several changes to the T classifications from the previous 7th edition staging system (Table 2) . 5, 6 Previously, early HCC were Although multiple changes have been made in the AJCC 8th edition staging system, their impact on the prognostic value of the staging system has yet to be evaluated. Hence, we sought to validate the 8th edition staging system for HCC using a population-based data set. In particular, we sought to whether the staging of early HCC is appropriate, specifically whether further subdivision of T2 tumors should be considered. This enables a valid appraisal of the new staging system for HCC.
International Classification of Disease 3rd edition (ICD-O3) were used to identify HCC using site codes C220. Histology codes were used to specifically identify patients with HCC (8170-8175). Other variants of HCC and non-specific histologies (eg, "neoplasm" or "carcinoma, NOS,") were excluded from the analysis. Likewise, cases with vague histology codes of "neoplasm" (8000-8003), "carcinoma, NOS" (8010-8013), and "carcinoma undifferentiated, NOS" (8120-8122) were excluded (NOS, not otherwise specified).
The AJCC 7th and 8th edition staging systems were derived using data on tumor size, lymph node involvement, number of tumors and vascular invasion, all of which are provided by the SEER database. In this study, c-indices were not calculated for patients with N1
classification due to small numbers. Cases with missing data for these variables were excluded.
| Statistical analysis
Categorical variables were compared using the chi-squared test. Nonnormally distributed data were analyzed using the MannWhitney U test. Overall survival was estimated using Kaplan-Meier survival curves and compared using the log-rank test. Overall survival was chosen because this is the survival metric used by the AJCC and avoids potential bias from attribution of cause of death. A concordance index (c-index) was calculated to evaluate the discriminatory power of each staging system. 7 A value of 0.5 indicates chance alone is as predictive as the staging system, whereas a level of 1.0 signifies perfect concordance. A Cox proportional hazards model was used with T classification coded as indicator variables to obtain hazard ratios (HR), and the concordance index was calculated from this Cox model. 8 Cox proportional hazards modeling was also used to assess differences in survival after resection vs transplant. A separate model adjusting for potential confounding variables including sex, age, and race was also assessed. Stratified analyses were also carried out to examine impact of the staging systems in patients undergoing resection and transplantation separately, and c-indices for these subgroups were separately evaluated. A P-value of <0.05 was considered to be statistically significant. Data analysis were performed using R Foundation Statistical software (R 3.2.1) with TableOne, ggplot2, Hmisc, and survival packages (R Foundation for Statistical Computing, Vienna, Austria).
3 | RESULTS
| Patient demographics and time trends
This study cohort included 8918 patients who underwent surgery for HCC between 1998 and 2013. Clinicopathologic data for the entire cohort are presented in Supplemental Table S1 . In this cohort, 5590
(63%) of patients had a surgical resection, and 3328 (37%) patients
received a liver transplant. Only 19% (1540/8918) of patients in the entire cohort had lymph nodes examined. Among patients undergoing liver resection, the rate of lymph node examination was 14% (772/ 5594), significantly lower than among those receiving a liver transplant (26%, 870/3328, P < 0.001). Of those with at least one 1 lymph node examined, the median number examined was 1 (interquartile range, IQR 1-2), and the incidence of positive lymph nodes was 5%. In patients undergoing surgical resection, the incidence of positive lymph nodes was 9% (68/702), higher than in patients receiving liver transplant for HCC (1%, 12/852). Figure 2 ).
| Impact of vascular invasion
Our analysis confirmed that for T1 tumors, vascular invasion does not impact prognosis (median survival 50 vs 51 months, P = 0.5, Supplemental Table S2 
| Impact of tumor size in multifocal tumors
We also evaluated the impact of tumor size on multifocal tumors using a cut-off of 5 cm, as does the AJCC 8th edition staging system. In this analysis, 69% (1750/2536) of patients had multifocal tumors ≤5 cm and the remaining 31% (786/2536) had multifocal tumors >5 cm.
Survival was significantly longer among patients with multifocal However, this study may have been underpowered, as there were relatively few patients with solitary HCC >2 cm with microvascular invasion (n = 334) and multifocal tumors ≤5 cm (n = 80). In our study, there were significant differences in survival between these two subgroups, both in the liver resection and transplant groups. Hence, substratifying the T2 group further to differentiate solitary and multifocal tumors is warranted.
Our analyses also demonstrate that microvascular invasion confers an adverse prognosis in multifocal T2 tumors. However, the current AJCC staging system does not take this into account.
Microvascular invasion has been associated with adverse prognosis in most studies. [13] [14] [15] [16] A recent meta-analysis of pooled studies demonstrated that microvascular invasion has prognostic value following resection and transplantation and is closely associated with increasing tumor size and multifocal disease. 17 
